Literature DB >> 17234133

Molecular Trojan horses for blood-brain barrier drug delivery.

William M Pardridge1.   

Abstract

Molecular Trojan horses are genetically engineered proteins that cross the blood-brain barrier (BBB) via endogenous receptor-mediated transport processes. Molecular Trojan horses provide a brain drug targeting technology that allows for the non-invasive delivery of large molecule therapeutics to the human brain. The development of BBB drug targeting technology is an arcane area of discovery medicine that suffers from chronic under-development.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17234133

Source DB:  PubMed          Journal:  Discov Med        ISSN： 1539-6509            Impact factor:   2.970


  20 in total

1.  Expression, purification, and characterization of recombinant human transferrin from rice (Oryza sativa L.).

Authors:  Deshui Zhang; Somen Nandi; Paula Bryan; Steve Pettit; Diane Nguyen; Mary Ann Santos; Ning Huang
Journal:  Protein Expr Purif       Date:  2010-05-04       Impact factor: 1.650

Review 2.  Targeting the neurovascular unit for treatment of neurological disorders.

Authors:  Reyna L Vangilder; Charles L Rosen; Taura L Barr; Jason D Huber
Journal:  Pharmacol Ther       Date:  2010-12-21       Impact factor: 12.310

3.  From the liver to the brain across the blood-brain barrier.

Authors:  Vivian I Teichberg
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-26       Impact factor: 11.205

Review 4.  In-vitro blood-brain barrier modeling: A review of modern and fast-advancing technologies.

Authors:  Farzane Sivandzade; Luca Cucullo
Journal:  J Cereb Blood Flow Metab       Date:  2018-07-30       Impact factor: 6.200

Review 5.  Ultrasound-induced blood-brain barrier opening.

Authors:  Elisa E Konofagou; Yao-Sheng Tung; James Choi; Thomas Deffieux; Babak Baseri; Fotios Vlachos
Journal:  Curr Pharm Biotechnol       Date:  2012-06       Impact factor: 2.837

6.  Development of the CNS TAP tool for the selection of precision medicine therapies in neuro-oncology.

Authors:  Joseph R Linzey; Bernard L Marini; Amy Pasternak; Cory Smith; Zac Miklja; Lili Zhao; Chandan Kumar-Sinha; Alyssa Paul; Nicholas Harris; Patricia L Robertson; Lindsey M Hoffman; Arul Chinnaiyan; Rajen Mody; Carl Koschmann
Journal:  J Neurooncol       Date:  2017-12-12       Impact factor: 4.130

7.  Therapeutic immune clearance of rabies virus from the CNS.

Authors:  D Craig Hooper; Anirban Roy; Rhonda B Kean; Timothy W Phares; Darryll A Barkhouse
Journal:  Future Virol       Date:  2011-03-01       Impact factor: 1.831

Review 8.  The Promises and Challenges of Erythropoietin for Treatment of Alzheimer's Disease.

Authors:  Jiahong Sun; Jan Michelle Martin; Victoria Vanderpoel; Rachita K Sumbria
Journal:  Neuromolecular Med       Date:  2019-01-17       Impact factor: 3.843

9.  Blood-brain barrier-adapted precision medicine therapy for pediatric brain tumors.

Authors:  Bernard L Marini; Lydia L Benitez; Andrew H Zureick; Ralph Salloum; Angela C Gauthier; Julia Brown; Yi-Mi Wu; Dan R Robinson; Chandan Kumar; Robert Lonigro; Pankaj Vats; Xuhong Cao; Katayoon Kasaian; Bailey Anderson; Brendan Mullan; Benjamin Chandler; Joseph R Linzey; Sandra I Camelo-Piragua; Sriram Venneti; Paul E McKeever; Kathryn A McFadden; Andrew P Lieberman; Noah Brown; Lina Shao; Marcia A S Leonard; Larry Junck; Erin McKean; Cormac O Maher; Hugh J L Garton; Karin M Muraszko; Shawn Hervey-Jumper; Jean M Mulcahy-Levy; Adam Green; Lindsey M Hoffman; Katie Dorris; Nicholas A Vitanza; Joanne Wang; Jonathan Schwartz; Rishi Lulla; Natasha Pillay Smiley; Miriam Bornhorst; Daphne A Haas-Kogan; Patricia L Robertson; Arul M Chinnaiyan; Rajen Mody; Carl Koschmann
Journal:  Transl Res       Date:  2017-08-10       Impact factor: 7.012

Review 10.  Brain-derived neurotrophic factor in neurodegenerative diseases.

Authors:  Chiara Zuccato; Elena Cattaneo
Journal:  Nat Rev Neurol       Date:  2009-06       Impact factor: 42.937
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.